Vaccine of domestic first type influenza gets permission to produce and used in the human body to inoculate formally

Vaccine of domestic first type influenza gets permission to produce and used in the human body to inoculate formally
Will it be today such as electricity August 31 such as www.chinanews.com, national the intersection of food and medicines supervise administration bureau organize to hold first type vaccine of H1N1 influenza expert, can comment to examine, through appraising through discussion, has already been examined through the expert panel by the first type H1N1 influenza vaccine which star of Beijing department biologicals Co., Ltd. produced, and get permission to produce and used in the human body and inoculate formally.
According to arranging, China will produce vaccine very available for people of 1% of China before the end of September, and the listing of vaccine will be arranged in unison according to prevention and control, will not rush to purchase. It says, the use of vaccine should emphasize the immune tactics before this that the hygiene of Ministry of Public Health meets an urgent need and runs to Deputy Director Liang WanNian, not all people inoculate. The expert is studying the final inoculation tactics of vaccine, will " list key crowd, high-risk group possibly, with what kind of order and under some states to inoculate "
Chinese health minister Chen Zhu expresses during attending the council of ministers of the hygiene of the world in July too, China has 1,300 million people, it is very difficult to offer vaccine to everybody at the same time in a short time. So, once vaccine enters and inoculates stage, the first step will inoculate vaccine to more easily infected group, for example pregnant woman, crowd and worker in the special field who has the basic disease. Committee of Experts of Ministry of Public Health will produce the characteristic of the state of development according to the domestic and foreign epidemic situation too, adjusting the tactics dynamically constantly.
It is reported, national food medicines supervise the administration bureau already receiving the application that the blue biotech firm of China of Xinxiang of Henan has filed too, and tomorrow, examine and comment to the first type H1N1 influenza vaccine that it produces.
Vaccine produces the significant events
June 8, first type the intersection of H1N1 and the intersection of influenza and vaccine produce with malicious of NYMCX-179A transporting to the department of Beijing and revitalizing biologicals Co., Ltd., scientific research personnel start malicious seeds to criticize and prepare the job, indicate the batch process of first type H1N1 vaccine is started formally rapidly.
On June 13, the department of Beijing revitalizes biologicals Co., Ltd. to reveal, the preparation of first type H1N1 influenza vaccine is still in " seeds " At cultivation stage of the virus, the first batch of vaccine will go into operation in Beijing formally in one week.
June 15, Beijing department revitalize the intersection of biologicals and Co., Ltd., finish first type the intersection of H1N1 and the intersection of influenza and malicious seeds of vaccine criticize and prepare to work, and puts the first batch of vaccine into operation formally on the same day.
On July 22, the department of Beijing revitalizes the first type H1N1 influenza vaccine that biologicals Co., Ltd. produced, after finishing the biological, biochemical experiment, begin the clinical trial formally. 1614 volunteers are divided the seniors class (101) over 60 into , group of adult of 18-60 years old (706) , juniors class of 12-17 years old (404) , group of children of 3-11 years old (403) Wait for four groups to inoculate the test, among them, the seniors class inoculates a stitch; Adult's group, juniors class and children group inoculate 2 stitches.
July 28, Beijing department revitalize the intersection of biologicals and Co., Ltd., say first type the intersection of H1N1 and the intersection of influenza and clinical experiment work of vaccine make good progress, all experimenters finish the first stitch inoculating and observation of security of 3 days, there is no serious bad reaction report, the preliminary result reveals vaccine is safe and reliable.
On August 12, first type H1N1 influenza vaccine clinical trial experimenters begin to inoculate the second stitch, Chen Zhu, minister of Ministry of Public Health, finishes the second stitch to inoculate on the afternoon of the 11th as the first experimenter. In the inoculation in the first stitch vaccine is observed, serious bad reaction or incident has not taken place, initial analysis reveals, it is safe and reliable for the first type H1N1 influenza test which China produces to use vaccine.
On August 18, star of Beijing department biologicals Co., Ltd. announces, its first type H1N1 influenza vaccine clinical trial produced is finished, this is a global first first type H1N1 influenza vaccine clinical trial that finishes being appraised tentatively too. The preliminary result reveals vaccine is safe and effective to the human body.
The analysis result reveals, the clinical trial can produce good immunoreaction after inoculating a stitch while using vaccine, indicate vaccine inoculation can protect the human body. No serious bad reaction will be appeared experimenter after inoculating,bad reaction in order to slightly, pass by response of sex as main fact one, main symptom pains in order to inject the position, indicate vaccine has good security.
First shed vaccine 123
Will store according to 1% of the proportions of population
June 29, Ministry of Public Health hygiene meet an urgent need, run the intersection of Deputy Director and Wan Liang, answer the intersection of The Beijing News and reporter, say when the questions every year, before October 1, China will store vaccine according to 1/100 of the proportions of population's, popular strategic reserves vaccine breaks out by a large scale as should flow to first ing, the vaccine will not be listed.
Wan Liang say, flow first storage level of vaccine target in the intersection of population and " 1% " of quantity every year ,Having considered the present tactics of prevention and control in China synthetically, and more easily infected group and production capacity of the vaccine manufacturer, and the decision made.
First flows vaccine must inoculate two stitches
Beijing vaccine develop the intersection of enterprise and relevant person in charge, introduce when being interviewed by The Beijing News reporter, because first type H1N1 influenza virus is the new virus, the health of most people has no immunity to it at all, so global multinational the intersection of vaccine and seminar, think first inoculate two stitches must shed vaccine, generally at present, in order to the internal immunity of persons who strengthen inoculating. And seasonal influenza will come every year, has already had basic immunity in most human body, inoculate a stitch every year, strengthen the immunity by itself.
The price of vaccine or no higher than 30 yuan
On May 24, The Beijing News reports, national influenza is great vaccine prevails to prepare the person in charge of enterprises to reveal on the 23rd, at present, producer prices of vaccine of ordinary influenza are about 30 yuans. Because first flows vaccine is researched and developed independently at home, so, the price should be unable to be higher than the price of vaccine of ordinary influenza.
On June 11, biotechnology general manager of Co., Ltd. Gao QingFang of long life in Changchun expresses when being interviewed by Chinese radio network reporter, as to the price of vaccine, not easy to make the accurate judgement now, the price of seasonal vaccine is 60 to 70 yuan at present, should be unable to be higher than this standard.

|